Michelle C. Miller

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris et al. · New England Journal of Medicine · 2016 · 1.9K citations · Full text

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

Dennis J. Slamon, Patrick Neven, Stephen Chia et al. · Journal of Clinical Oncology · 2018 · 1.1K citations

Advanced Breast Cancer, Fulvestrant V Placebo, Breast Oncology +15

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

Fabrice André, Eva Ciruelos, Dejan Juric et al. · Annals of Oncology · 2020 · 557 citations · Full text

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Luigi Formisano, Yao Lu, Alberto Servetto et al. · Nature Communications · 2019 · 383 citations · Full text

Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open‐label clinical trial

Deborah Friedman, Carolina Llanos, Peter Izmirly et al. · Arthritis & Rheumatism · 2010 · 237 citations · Full text